FBIO Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -80.55% compared to Fortress Biotech's net margin of -49.65%. Fortress Biotech's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Fortress Biotech has a consensus price target of $10.00, signalling upside risk potential of 418.14%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that Fortress Biotech has higher upside potential than NovaBay Pharmaceuticals, analysts believe Fortress Biotech is more attractive than NovaBay Pharmaceuticals.

Fortress Biotech has a beta of 1.752, which suggesting that the stock is 75.204% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Fortress Biotech quarterly revenues are $13.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Fortress Biotech's net income of -$10.6M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Fortress Biotech's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.76x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -80.55% compared to Fortress Biotech's net margin of --. Fortress Biotech's return on equity of -- beat Oragenics's return on equity of --.

Fortress Biotech has a consensus price target of $10.00, signalling upside risk potential of 418.14%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1998.11%. Given that Oragenics has higher upside potential than Fortress Biotech, analysts believe Oragenics is more attractive than Fortress Biotech.

Fortress Biotech has a beta of 1.752, which suggesting that the stock is 75.204% more volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Fortress Biotech quarterly revenues are $13.1M, which are larger than Oragenics quarterly revenues of --. Fortress Biotech's net income of -$10.6M is lower than Oragenics's net income of -$2.2M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.76x versus 0.46x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical has a net margin of -80.55% compared to Fortress Biotech's net margin of -108.46%. Fortress Biotech's return on equity of -- beat Ultragenyx Pharmaceutical's return on equity of -205.06%.

Fortress Biotech has a consensus price target of $10.00, signalling upside risk potential of 418.14%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $87.21 which suggests that it could grow by 218.17%. Given that Fortress Biotech has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Fortress Biotech is more attractive than Ultragenyx Pharmaceutical.

Fortress Biotech has a beta of 1.752, which suggesting that the stock is 75.204% more volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.261, suggesting its less volatile than the S&P 500 by 73.884%.

Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

Fortress Biotech quarterly revenues are $13.1M, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $139.3M. Fortress Biotech's net income of -$10.6M is higher than Ultragenyx Pharmaceutical's net income of -$151.1M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.76x versus 4.34x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -80.55% compared to Fortress Biotech's net margin of --. Fortress Biotech's return on equity of -- beat Theriva Biologics's return on equity of --.

Fortress Biotech has a consensus price target of $10.00, signalling upside risk potential of 418.14%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than Fortress Biotech, analysts believe Theriva Biologics is more attractive than Fortress Biotech.

Fortress Biotech has a beta of 1.752, which suggesting that the stock is 75.204% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Fortress Biotech quarterly revenues are $13.1M, which are larger than Theriva Biologics quarterly revenues of --. Fortress Biotech's net income of -$10.6M is lower than Theriva Biologics's net income of -$4.3M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.76x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.